---
document_datetime: 2023-09-21 17:21:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/raptiva-epar-procedural-steps-taken-authorisation_en.pdf
document_name: raptiva-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3988165
conversion_datetime: 2025-12-22 10:06:30.161594
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Serono  Europe  Limited  submitted  on  6  February  2003  an  application  for  Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Raptiva, in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to Council Regulation No (EEC) 2309/93 of 22 July 1993.

<!-- image -->

- During the meeting on 22 - 23 June the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Raptiva on 23 June 2004.

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: B. van Zwieten-Boot Co-Rapporteur: J. Ersbøll Licensing status: The  product  was  not  licensed  in  any  country  at  the  time  of  submission  of  the  application.  A  new application was filed in the following countries: USA, where it has been subsequently authorised. 2. Steps taken for the assessment of the product · The procedure started on 24 February 2003. · The Rapporteur's first assessment report was circulated to all CHMP Members on 7 May 2003. The Co-Rapporteur's first assessment report was circulated to all CHMP Members on 12 May 2003. · During  the  meeting  on  24  -  26  June  2003  the  CHMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the company on 27 June 2003. · The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  16  December 2003. · The Rapporteurs circulated the response assessment report on the company's responses to the list of questions to all CHMP Members on 2 February 2004. · During the CHMP meeting on 24-26 February 2004, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on  17 May 2004. · During  the  CHMP  meeting  on  1-3  June  2004,  outstanding  issues  were  addressed  by  the applicant during an oral explanation before the CHMP. The CHMP subsequently adopted a list of remaining issues to be addressed in writing by the Applicant. · The  applicant  submitted  the  written  responses  to  the  CHMP  consolidated  List  of  remaining issues on 7 June 2004. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of remaining issues to all CHMP members on  15 June 2004. · The applicant submitted the written responses to the CHMP consolidated List of outstanding issues on 16 April 2004.

- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 20 September 2004.